First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

This study has been terminated.
(Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns were present)
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01261767
First received: December 14, 2010
Last updated: April 15, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2011
  Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)